Publications/patents
Our team advances its research through high-quality publications while safeguarding the intellectual property that enables translation. Working with the University of Tartu TTO, we pursue a proactive and balanced strategy — open scientific communication complemented by responsible IP protection — to ensure that next-generation precision drugs and nanomedicines can make the greatest impact.
Patents
Find our patents at Espacenet and Estonian Research Information System.
Publications
*In reverse chronological order, full list on Google Scholar.
- LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme
- LinTT1-Functionalized Hybrid Lipid-Polymer Nanoparticles for Glioblastoma Targeting
- Peptide-targeted nanoparticles for tumor therapy
- Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide
- Advancing Cancer-Targeted Nanotherapies with Tumor Homing Peptides
- Identification of splenic IRF7 as a nanotherapy target for tele-conditioning myocardial reperfusion injury
- Screening of homing and tissue-penetrating peptides by microdialysis and in vivo phage display
- Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer
- Effects of LinTT1-peptide conjugation on the properties of poly(ethylene glycol)-block-(ε-caprolactone) nanoparticles prepared by the nanoprecipitation method
- A Cyclic Peptide Targets Glioblastoma by Binding to Aberrantly Exposed SNAP25
- A CYCLIC PEPTIDE TARGETS GLIOBLASTOMA BY BINDING TO ABERRANTLY EXPOSED SNAP25
- Unlocking the potential of nanomedicine: advances in precision targeting strategies
- Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy
- PL3 CendR peptide shows specific uptake in cultured Y79 retinoblastoma cells with nucleolar accumulation
- Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation
- Brain Targeting Nanomedicines: Pitfalls and Promise
- Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions
- Novel Anthracycline Utorubicin for Cancer Therapy
- Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer
- Intravitreal CendR peptides target laser-induced choroidal neovascularization sites in mice
- Targeting of Tomato Bushy Stunt Virus with a Genetically Fused C-End Rule Peptide
- Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice
- Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation
- SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner
- ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1
- Editorial on Special Issue "Precision Delivery of Drugs and Imaging Agents with Peptides"
- Preclinical Validation of Tumor-Penetrating and Interfering Peptides against Chronic Lymphocytic Leukemia
- PL1 Peptide Engages Acidic Surfaces on Tumor-Associated Fibronectin and Tenascin Isoforms to Trigger Cellular Uptake
- Homing Peptide-Based Targeting of Tenascin-C and Fibronectin in Endometriosis
- Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction
- A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction
- New Tools for Streamlined In Vivo Homing Peptide Identification
- Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma
- Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics
- P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas
- Novel Anthracycline Utorubicin for Cancer Therapy
- Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
- LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy
- Homing Peptides for Cancer Therapy
- In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues